Creado en 2006 (Francia), I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome posee 2757 marcas hermanas y 17478 marcas de la competencia. La marca I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome es propiedad de SANOFI, una empresa que cotiza en Paris. El ISIN, codigo bursatil de empresa, es FR0000120578. El sector de I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome es Fabricantes de medicamentos.

I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome es una marca comercial de SANOFI (SAN) actualidad

Depósito internacional : 2006 Sector de actividad Fabricantes de medicamentos

Toda la actualidad Marketscreener Logo
SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome)

loader
Bolsa de valores: más información sobre SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome) Marketscreener Logo